GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for GSK
38.75
-0.30 (-0.77%)
Aug 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 38.71 - 38.98
52 week 37.20 - 44.54
Open 38.96
Vol / Avg. 2.46M/2.69M
Mkt cap 93.54B
P/E 44.03
Div/yield 0.50/6.42
EPS 0.88
Shares 4.92B
Beta 1.03
Inst. own 5%
Oct 25, 2017
Q3 2017 GlaxoSmithKline PLC Earnings Release Add to calendar
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Call - Webcast
Jul 26, 2017
Q2 2017 GlaxoSmithKline PLC Earnings Release
Jul 19, 2017
Emergent BioSolutions Inc to Discuss Acquisition of Raxibacumab from GlaxoSmithKline PLC Conference Call - Webcast
May 22, 2017
GlaxoSmithKline PLC at UBS Global Healthcare Conference (One-on-One)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 16.56% 3.81%
Operating margin 23.27% 9.32%
EBITD margin - 33.06%
Return on average assets 8.29% 1.89%
Return on average equity 295.67% 29.24%
Employees 99,827 -
CDP Score - A

Address

980 Great West Road
BRENTFORD, TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Officers and directors

Emma Walmsley Chief Executive Officer - Designate, Executive Director
Age: 46
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 52
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D, Executive Director
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Abbas Hussain President - Global Pharmaceuticals
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Global Pharmaceuticals
Bio & Compensation  - Reuters
Luke Miels President - Global Pharmaceuticals
Bio & Compensation  - Reuters
Daniel E Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters
Nick Hirons Senior Vice President – Global Ethics and Compliance
Bio & Compensation  - Reuters